• SHARE

The Food and Drug Administration is already limiting one of the most controversial drug approvals in its 115-year history.

The medication is Biogen Inc.’s Alzheimer’s treatment Aduhelm, which won clearance recently despite mixed evidence and expert objections. The agency initially approved the drug for most Alzheimer’s patients, even though it was only studied in those with mild disease.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)